Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
---|---|---|---|---|---|---|
Income Statement | ||||||
Total Revenue | 886.89M | 894.66M | 924.22M | 822.45M | 527.16M | 468.46M |
Gross Profit | 411.42M | 421.38M | 463.90M | 405.95M | 243.01M | 215.06M |
EBITDA | -1.01B | -935.82M | 182.60M | 122.30M | 107.89M | 98.30M |
Net Income | -1.04B | -1.09B | -9.42M | -22.87M | 48.31M | 60.88M |
Balance Sheet | ||||||
Total Assets | 3.38B | 3.44B | 4.55B | 4.55B | 992.93M | 920.19M |
Cash, Cash Equivalents and Short-Term Investments | 138.88M | 129.00M | 170.94M | 245.57M | 381.05M | 381.09M |
Total Debt | 792.53M | 914.27M | 906.24M | 900.00M | 986.69M | 1.29M |
Total Liabilities | 1.26B | 1.37B | 1.40B | 1.42B | 105.56M | 79.81M |
Stockholders Equity | 2.12B | 2.07B | 3.14B | 3.13B | 887.37M | 840.38M |
Cash Flow | ||||||
Free Cash Flow | 76.44M | -46.35M | -76.16M | -24.73M | 43.61M | 54.38M |
Operating Cash Flow | 87.01M | 58.24M | 35.26M | 41.03M | 68.04M | 81.09M |
Investing Cash Flow | 32.19M | -99.19M | -29.31M | 201.04M | -97.23M | -105.56M |
Financing Cash Flow | -101.97M | -1.60M | 1.92M | -118.08M | 6.81M | 33.54M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
70 Outperform | $3.31B | ― | -17.68% | ― | 22.37% | 86.08% | |
61 Neutral | $729.72M | ― | -4.54% | ― | 4.31% | 69.57% | |
56 Neutral | $1.35B | ― | -11.76% | ― | 9.70% | -30.94% | |
55 Neutral | $735.05M | ― | -70.03% | ― | 3.83% | -137.31% | |
52 Neutral | $1.21B | ― | -13.16% | ― | -7.31% | 29.84% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $1.28B | ― | -39.71% | ― | -2.77% | -4327.53% |
Neogen Corporation is a global leader in food and animal safety, providing comprehensive solutions across the Food Safety, Livestock, and Pet Health & Wellness markets. The company operates in over 140 countries, leveraging science and technology to enhance global food security and well-being.
Neogen’s recent earnings call presented a mixed sentiment, reflecting both optimism and challenges. The company reported improvements in revenue and cash flow, alongside strategic cost-cutting measures. However, these positives were tempered by significant challenges in the Food Safety segment and inefficiencies in inventory and sample collection. Regional performance was uneven, with the APAC region facing notable headwinds.
Neogen Corporation announced on September 15, 2025, that its Chief Financial Officer and Chief Operating Officer, David Naemura, intends to resign to pursue other opportunities. His decision is not due to any disagreements with the company. Naemura will stay on until the end of the year to assist with the transition to a new CFO. The company has entered into a transition agreement with Naemura, which includes a bonus incentive if he remains until December 31, 2025.
The most recent analyst rating on (NEOG) stock is a Hold with a $5.50 price target. To see the full list of analyst forecasts on Neogen stock, see the NEOG Stock Forecast page.
On August 15, 2025, Neogen Corporation announced changes to its fiscal 2026 long-term incentive compensation plan for its executive management team, introducing performance share units (PSUs) alongside stock options. This strategic move aims to align executive compensation with the company’s transformational and strategic goals, as well as market performance. The PSUs are based on performance metrics such as revenue growth, adjusted EBITDA margin expansion, and cash flow conversion over a three-year period. Additionally, stock options were granted to executives, including CEO Mikhael Nassif, as part of their compensation package, with the options vesting over three years and having a ten-year term.
The most recent analyst rating on (NEOG) stock is a Hold with a $5.00 price target. To see the full list of analyst forecasts on Neogen stock, see the NEOG Stock Forecast page.
Neogen Corporation announced the retirement of William T. Boehm from its Board of Directors, effective October 23, 2025, after serving since 2011. Boehm’s contributions have been pivotal in shaping the company’s strategic direction and growth. Concurrently, Avi Pelossof has been appointed to the Board, effective October 24, 2025. Pelossof brings over 25 years of experience in the diagnostics market, having previously led Immucor Inc. through a successful turnaround and acquisition. His expertise is expected to provide valuable insights and drive innovation and growth for Neogen.
The most recent analyst rating on (NEOG) stock is a Hold with a $16.50 price target. To see the full list of analyst forecasts on Neogen stock, see the NEOG Stock Forecast page.
Neogen Corporation is a global leader in food safety, livestock, and pet health and wellness, providing comprehensive solutions through science and technology to ensure global food security. The company recently reported its fourth-quarter 2025 earnings, highlighting a revenue of $225.5 million and a significant net loss of $612.2 million, primarily due to a non-cash goodwill impairment related to a past acquisition. Despite the challenges, Neogen’s core mission remains focused on enhancing food safety and security worldwide.
Neogen’s recent earnings call painted a mixed picture, with strategic initiatives and product launches being overshadowed by financial challenges. While the company made strides in pathogen detection and regulatory developments, revenue declines, production inefficiencies, and a significant goodwill impairment charge weighed heavily on the overall sentiment.
On July 24, 2025, Neogen Corporation announced the appointment of Mikhael Nassif as President and Chief Executive Officer, effective August 11, 2025. Mr. Nassif brings extensive leadership experience from his previous roles at Siemens Healthineers, Baxter International Inc., Anheuser-Busch InBev, and Johnson & Johnson. His compensation package includes an annual base salary of $800,000, participation in the Incentive Compensation Plan, and a long-term incentive plan, among other benefits. This strategic leadership change is expected to influence Neogen’s operational direction and potentially impact its market positioning.
The most recent analyst rating on (NEOG) stock is a Hold with a $16.50 price target. To see the full list of analyst forecasts on Neogen stock, see the NEOG Stock Forecast page.